Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
New patient/caregiver resource from the National Comprehensive Cancer Network focuses on small cell lung cancer, an aggressive cancer.
Imfinzi plus chemotherapy led to a modest but significant improvement in overall survival.
After a small-cell lung cancer (SCLC) diagnosis, you need education, support, access to care and help with finances.
This issue explores various treatment options for small-cell lung cancer and ways to manage side effects.
Chemotherapy, immunotherapy and radiation are the mainstays of SCLC treatment.
Cosela (trilaciclib) is given before chemotherapy to protect bone marrow function.
November is Lung Cancer Awareness Month.
Here are latest arrivals approved by the Food and Drug Administration.
Scientists discover a single gene’s role in drug resistance and look for ways to re-sensitize tumors to chemotherapy.
Lurbinectedin shrank tumors in a third of people with this less common type of lung cancer.
Additions of the checkpoint inhibitor led to improved survival compared with chemotherapy alone.
Although the improvement in survival with immunotherapy was modest, it is noteworthy because SCLC has been such a recalcitrant disease.
New immunotherapy option approved for uncommon, aggressive type of lung cancer.
A Phase II trial reached its primary endpoint of overall response in just over a third of participants.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.